| Date | Form | Description | Docs | XBRL | Pages |
| 06/02/17 | 8-K | Current report filing |
|
28 | |
| 05/26/17 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
32 |
| 05/17/17 | 8-K | Current report filing |
|
30 | |
| 05/15/17 | 424B2 | Prospectus filed pursuant to Rule 424(b)(2) |
|
51 | |
| 05/11/17 | 424B2 | Prospectus filed pursuant to Rule 424(b)(2) |
|
51 | |
| 04/13/17 | 8-K | Current report filing |
|
3 | |
| 04/10/17 | EFFECT | Notice of Effectiveness |
|
1 | |
| 04/06/17 | CORRESP | A correspondence can be sent as a document with another submission type or can be sent as a separate submission. |
|
1 | |
| 04/05/17 | 8-K | Current report filing |
|
4 | |
| 04/04/17 | 4 | Statement of changes in beneficial ownership of securities |
|
1 |
Latest News & Events
Anixa Biosciences to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20th
Read More...Anixa Biosciences Receives Notice of Allowance from U.S. Patent and Trademark Office for CAR-T Technology, Further Strengthening its Robust Intellectual Property Portfolio
Read More...Anixa Biosciences Receives Notice of Allowance from U.S. Patent and Trademark Office for Patent Covering Breast Cancer Vaccine Technology
Read More...